Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Withdrawn 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Neoplasms 3Smoking 1Pulmonary Disease, Chronic Obstructive 1Pancreatic Neoplasms 1Neurologic Manifestations 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Lymphoma, Follicular 1Leukemia, Myeloid, Acute 1Hyperlipoproteinemia Type II 1Hematologic Neoplasms 1Diabetes Mellitus 1Dementia 1Colorectal Neoplasms 1Colitis, Ulcerative 1Cardiovascular Diseases 1Carcinoma, Hepatocellular 1COVID-19 1

Interventions

Gemcitabine 42130-nm albumin-bound paclitaxel 26Albumin-Bound Paclitaxel 18Irinotecan 16Oxaliplatin 14Fluorouracil 14pembrolizumab 13Nivolumab 13Magnetic Resonance Spectroscopy 11Leucovorin 11Taxes 10Specimen Handling 9Biopsy 9Cisplatin 8Capecitabine 7folfirinox 6Radiotherapy 6Carboplatin 6irinotecan sucrosofate 5durvalumab 5Ipilimumab 5Cyclophosphamide 5olaparib 4defactinib 4Surveys and Questionnaires 4Standard of Care 4Radiosurgery 4Immunoglobulin G 4Disulfides 4dehydroftorafur 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Pancreatic Neoplasms × Atorvastatin × Clear all
NCT04862260 2026-03-19

Cholesterol Disruption in Combination With the Standard of Care in Patients With Advanced Pancreatic Adenocarcinoma

CHU de Quebec-Universite Laval

Phase EARLY_PHASE1 Active not recruiting
3 enrolled
Gastrointestinal

Hyperlipoproteinemia Type II, Neoplasm Metastasis, Neoplasms, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡